Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

932
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
932
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Experience With Extravascular Implantable Cardioverter-Defibrillator Under Deep Sedation.

Pacing and clinical electrophysiology : PACE·2026
Same author

Performance of Vision-Enabled Large Language Models in Image-Based Electrocardiogram Interpretation: Exploratory Evaluation.

Journal of medical Internet research·2026
Same author

Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.

The New England journal of medicine·2026
Same author

Cost-effectiveness of catheter ablation in end-stage heart failure with atrial fibrillation: Insights from CASTLE-HTx.

Heart rhythm·2026
Same author

Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry.

European heart journal·2026
Same author

Three-Year Outcomes of Catheter Ablation in Patients With End-Stage Heart Failure and Atrial Fibrillation.

Circulation·2025

Related Experiment Video

Updated: Jun 21, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K

[Atrial fibrillation and heart failure].

Leonard Bergau1

  • 1Abteilung für Kardiologie und Pneumologie, Universitätsmedizin Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland. leonard.bergau@med.uni-goettingen.de.

Innere Medizin (Heidelberg, Germany)
|July 15, 2024
PubMed
Summary

Atrial fibrillation management is crucial for heart failure patients. Catheter ablation is preferred for systolic heart failure, but its effectiveness in diastolic heart failure requires further study.

Keywords:
Catheter ablationFrequency controlHeart failure, preserved ejection fractionHeart failure, reduced ejection fractionRhythm control

More Related Videos

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

1.7K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.5K

Related Experiment Videos

Last Updated: Jun 21, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

1.7K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.5K

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Research

Background:

  • Atrial fibrillation and heart failure are common cardiovascular diseases with significant mortality and morbidity.
  • These conditions are pathologically linked, often exacerbating each other.
  • Managing atrial fibrillation is integral to modern heart failure treatment.

Purpose of the Study:

  • To review the role of atrial fibrillation management in heart failure.
  • To evaluate catheter ablation as a treatment option for heart failure patients with atrial fibrillation.
  • To identify the need for further research in specific heart failure populations.

Main Methods:

  • Review of current data and clinical practice guidelines.
  • Analysis of evidence comparing catheter ablation with pharmacological therapy.
  • Identification of knowledge gaps in heart failure with preserved ejection fraction (HFpEF).

Main Results:

  • Sinus rhythm maintenance is recommended for systolic heart failure.
  • Catheter ablation demonstrates advantages over pharmacological therapy in systolic heart failure.
  • The efficacy of catheter ablation in diastolic heart failure (HFpEF) remains unclear.

Conclusions:

  • Catheter ablation is the treatment of choice for many heart failure patients with atrial fibrillation, particularly those with systolic dysfunction.
  • Further randomized studies are essential to clarify the role and efficacy of catheter ablation in patients with HFpEF.